ArticleCancers2026
Epigenetic Priming with Oral Decitabine/Cedazuridine Combined with Nivolumab in Unresectable or Metastatic Mucosal Melanoma: Clinical and Correlative Findings from a Phase Ib/II Trial.
Jessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, Claire M Muckle, Elizabeth N Katsnelson, Phaedra A Whitty, Luke Mantle, Sapna P Patel, Dexiang Gao, Kimberly R Jordan and 4 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Jessica S W BorgersDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-6478-7821 Cheng-Chang WuDepartment of Pediatrics, School of Medicine, University of Colorado Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0009-0001-2539-6860 Theresa M MedinaDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Claire M MuckleDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Elizabeth N KatsnelsonDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Phaedra A WhittyDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Luke MantleDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-0239-7032 Sapna P PatelDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Dexiang GaoDepartment of Pediatrics, School of Medicine, University of Colorado Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-3920-7060 Kimberly R JordanDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-8380-7157 William A RobinsonDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Richard P TobinDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Martin D McCarterDivision of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-8174-1713 Kasey L CoutsDivision of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-2088-2229 Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MNational Comprehensive Cancer NetworkNational Comprehensive Cancer Network 2021-IST-DECC-000076NCI NIH HHS P30 CA046934NIH HHS 5P30CA046934-38A60Patten-Davis Foundation
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
decitabine/cedazuridinemucosal melanomanivolumabRIG-Iviral mimicry
Identifiers
PMID42882866
PMCPMC13664269
What OpenQuestion holds
Textmetadata
Read underepoch 390